Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
61
AZN Quote, Financials, Valuation and Earnings
Last price:
$92.77
Seasonality move
:
1.93%
Day range:
$92.18 - $92.91
52-week range:
$61.24 - $94.02
Dividend yield:
1.69%
P/E ratio:
30.85x
P/S ratio:
4.99x
P/B ratio:
6.28x
Volume:
1.7M
Avg. volume:
5.4M
1-year change:
39.66%
Market cap:
$288B
Revenue:
$54.1B
EPS (TTM):
$3.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$14.6B | $1.26 | 4.56% | 128.14% | $98.96 |
|
AMGN
Amgen, Inc.
|
$8.7B | $5.04 | 4.54% | 310.03% | $325.88 |
|
BCYC
Bicycle Therapeutics Plc
|
$7.2M | -$0.82 | 92.62% | -25.75% | $21.50 |
|
GILD
Gilead Sciences, Inc.
|
$7B | $2.03 | 1.49% | 33.42% | $132.38 |
|
GSK
GSK Plc
|
$10.4B | $1.20 | 8.14% | 137.07% | $49.35 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.4B | $10.48 | -0.81% | 32.75% | $795.38 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$92.90 | $98.96 | $288B | 30.85x | $0.52 | 1.69% | 4.99x |
|
AMGN
Amgen, Inc.
|
$332.93 | $325.88 | $179.3B | 25.74x | $2.38 | 2.86% | 5.02x |
|
BCYC
Bicycle Therapeutics Plc
|
$6.82 | $21.50 | $473.1M | -- | $0.00 | 0% | 16.67x |
|
GILD
Gilead Sciences, Inc.
|
$124.70 | $132.38 | $154.7B | 19.31x | $0.79 | 2.53% | 5.39x |
|
GSK
GSK Plc
|
$49.08 | $49.35 | $98.6B | 14.00x | $0.42 | 3.41% | 2.41x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$784.97 | $795.38 | $82.5B | 18.79x | $0.88 | 0.45% | 6.07x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
41.56% | 0.163 | 13.71% | 0.66x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 2.129 | 1.21% | 9.36x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.042 | 18.1% | 1.16x |
|
GSK
GSK Plc
|
52.36% | -0.071 | 27.67% | 0.53x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$11.2B | $3.6B | 12.62% | 22.01% | 23.52% | $3.5B |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
GSK
GSK Plc
|
$8.5B | $3.5B | 19.21% | 42.84% | 30.08% | $1.8B |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen, Inc. has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 33.55%. AstraZeneca PLC's return on equity of 22.01% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of $98.96, signalling upside risk potential of 6.52%. On the other hand Amgen, Inc. has an analysts' consensus of $325.88 which suggests that it could fall by -2.12%. Given that AstraZeneca PLC has higher upside potential than Amgen, Inc., analysts believe AstraZeneca PLC is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 AMGNAmgen, Inc.10 15 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. Amgen, Inc. offers a yield of 2.86% to investors and pays a quarterly dividend of $2.38 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen, Inc.'s is not.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Amgen, Inc. quarterly revenues of $9.6B. AstraZeneca PLC's net income of $2.5B is lower than Amgen, Inc.'s net income of $3.2B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.85x while Amgen, Inc.'s PE ratio is 25.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.99x versus 5.02x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.99x 30.85x $15.1B $2.5B AMGNAmgen, Inc.5.02x 25.74x $9.6B $3.2B
-
Which has Higher Returns AZN or BCYC?
Bicycle Therapeutics Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of -503.67%. AstraZeneca PLC's return on equity of 22.01% beat Bicycle Therapeutics Plc's return on equity of -34.37%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M -
What do Analysts Say About AZN or BCYC?
AstraZeneca PLC has a consensus price target of $98.96, signalling upside risk potential of 6.52%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $21.50 which suggests that it could grow by 215.25%. Given that Bicycle Therapeutics Plc has higher upside potential than AstraZeneca PLC, analysts believe Bicycle Therapeutics Plc is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 BCYCBicycle Therapeutics Plc6 4 0 -
Is AZN or BCYC More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.475, suggesting its more volatile than the S&P 500 by 47.505%.
-
Which is a Better Dividend Stock AZN or BCYC?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or BCYC?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Bicycle Therapeutics Plc quarterly revenues of $11.7M. AstraZeneca PLC's net income of $2.5B is higher than Bicycle Therapeutics Plc's net income of -$58.7M. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.85x while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.99x versus 16.67x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.99x 30.85x $15.1B $2.5B BCYCBicycle Therapeutics Plc16.67x -- $11.7M -$58.7M
-
Which has Higher Returns AZN or GILD?
Gilead Sciences, Inc. has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 39.21%. AstraZeneca PLC's return on equity of 22.01% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About AZN or GILD?
AstraZeneca PLC has a consensus price target of $98.96, signalling upside risk potential of 6.52%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 6.16%. Given that AstraZeneca PLC has higher upside potential than Gilead Sciences, Inc., analysts believe AstraZeneca PLC is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 GILDGilead Sciences, Inc.16 8 0 -
Is AZN or GILD More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.
-
Which is a Better Dividend Stock AZN or GILD?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. Gilead Sciences, Inc. offers a yield of 2.53% to investors and pays a quarterly dividend of $0.79 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences, Inc.'s is not.
-
Which has Better Financial Ratios AZN or GILD?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Gilead Sciences, Inc. quarterly revenues of $7.8B. AstraZeneca PLC's net income of $2.5B is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.85x while Gilead Sciences, Inc.'s PE ratio is 19.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.99x versus 5.39x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.99x 30.85x $15.1B $2.5B GILDGilead Sciences, Inc.5.39x 19.31x $7.8B $3.1B
-
Which has Higher Returns AZN or GSK?
GSK Plc has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 25.09%. AstraZeneca PLC's return on equity of 22.01% beat GSK Plc's return on equity of 42.84%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B GSKGSK Plc73.8% $1.32 $45.1B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of $98.96, signalling upside risk potential of 6.52%. On the other hand GSK Plc has an analysts' consensus of $49.35 which suggests that it could grow by 0.54%. Given that AstraZeneca PLC has higher upside potential than GSK Plc, analysts believe AstraZeneca PLC is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 GSKGSK Plc1 5 1 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison GSK Plc has a beta of 0.470, suggesting its less volatile than the S&P 500 by 52.951%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. GSK Plc offers a yield of 3.41% to investors and pays a quarterly dividend of $0.42 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. GSK Plc pays out 94.89% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than GSK Plc quarterly revenues of $11.5B. AstraZeneca PLC's net income of $2.5B is lower than GSK Plc's net income of $2.9B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.85x while GSK Plc's PE ratio is 14.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.99x versus 2.41x for GSK Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.99x 30.85x $15.1B $2.5B GSKGSK Plc2.41x 14.00x $11.5B $2.9B
-
Which has Higher Returns AZN or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 16.69% compared to AstraZeneca PLC's net margin of 38.89%. AstraZeneca PLC's return on equity of 22.01% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC73.89% $0.81 $78.6B REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About AZN or REGN?
AstraZeneca PLC has a consensus price target of $98.96, signalling upside risk potential of 6.52%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $795.38 which suggests that it could grow by 1.33%. Given that AstraZeneca PLC has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe AstraZeneca PLC is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC8 1 0 REGNRegeneron Pharmaceuticals, Inc.14 8 0 -
Is AZN or REGN More Risky?
AstraZeneca PLC has a beta of 0.315, which suggesting that the stock is 68.471% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock AZN or REGN?
AstraZeneca PLC has a quarterly dividend of $0.52 per share corresponding to a yield of 1.69%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. AstraZeneca PLC pays 66.98% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or REGN?
AstraZeneca PLC quarterly revenues are $15.1B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. AstraZeneca PLC's net income of $2.5B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, AstraZeneca PLC's price-to-earnings ratio is 30.85x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.99x versus 6.07x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.99x 30.85x $15.1B $2.5B REGNRegeneron Pharmaceuticals, Inc.6.07x 18.79x $3.8B $1.5B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
